Baird raised the firm’s price target on Beta Bionics (BBNX) to $17 from $15 and keeps a Neutral rating on the shares. The firm updated its model following solid Q2 results but being left with remaining higher uncertainties.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics Reports Strong Q2 Growth and Raises Guidance
- Beta Bionics reports Q2 EPS (39c), consensus (47c)
- Beta Bionics raises FY25 revenue view to $88M-$93M from $82M-$87M
- Beta Bionics participates in a conference call with Lake Street
- Wells says CBP proposal for CGMs expected, insulin pumps inclusion ‘a surprise’